戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 g treatment with 50 nM Compound 49b, a novel beta-adrenergic receptor agonist.
2         This is reversed by isoproterenol, a beta-adrenergic receptor agonist.
3 or-mediated activation with isoproterenol, a beta-adrenergic receptor agonist.
4 ve agonist, or isoprenaline, a non-selective beta-adrenergic receptor agonist.
5 also sensitizes the channel to activation by beta-adrenergic receptor agonists.
6  was threefold greater than that elicited by beta-adrenergic receptor agonists.
7 solated neonatal cardiac myocytes exposed to beta-adrenergic receptor agonists.
8 F by preventing enhanced atrial responses to beta-adrenergic receptor agonists.
9 n the myocardium to exogenous and endogenous beta-adrenergic receptor agonists after burn injury may
10 haracteristics in response to treatment with beta-adrenergic receptor agonists and activators of aden
11 everal currently available therapies such as beta-adrenergic receptor agonists and antagonists, phosp
12                           Clinical trials of beta-adrenergic receptor agonists and cyclic nucleotide
13 all measured in response to isoproterenol, a beta-adrenergic receptor agonist, and carbachol, a choli
14                                              Beta-adrenergic receptor agonists are growth-promoting d
15 sed to cold temperatures or treated with the beta-adrenergic receptor agonist CL316,243 and that its
16           Administration of L-arginine and a beta-adrenergic receptor agonist (CL316, 243, respective
17                                              beta-Adrenergic receptor agonists had limited effects on
18 ion can inhibit the Cl- current activated by beta-adrenergic receptor agonists in guinea-pig ventricu
19               These studies demonstrate that beta-adrenergic receptor agonists in vitro can restore t
20                Chronic administration of the beta-adrenergic receptor agonist ISO increased the level
21                                          The beta-adrenergic receptor agonist isoprenaline (1 microM)
22 diated electrophysiological responses to the beta-adrenergic receptor agonist isoprenaline (Iso) in C
23 n/Hsp27 complex in response to the selective beta adrenergic receptor agonist isoproterenol, was subs
24  following intra-LS injections of either the beta-adrenergic receptor agonist isoproterenol (10 mug o
25              Angiotensin II (Ang II) and the beta-adrenergic receptor agonist isoproterenol (ISO) als
26                    Low concentrations of the beta-adrenergic receptor agonist isoproterenol (ISO) and
27                                          The beta-adrenergic receptor agonist isoproterenol (ISO) inc
28 ultures, we show that norepinephrine and the beta-adrenergic receptor agonist isoproterenol also inhi
29 ction were conducted using forskolin and the beta-adrenergic receptor agonist isoproterenol as agonis
30 er administration of either the nonselective beta-adrenergic receptor agonist isoproterenol or the be
31         Both angiotensin II (Ang II) and the beta-adrenergic receptor agonist isoproterenol selective
32 ions, ATP and UTP were not additive with the beta-adrenergic receptor agonist isoproterenol, but were
33 tion, either alone or in the presence of the beta-adrenergic receptor agonist isoproterenol, failed t
34  during periodic pacing in the presence of a beta-adrenergic receptor agonist isoproterenol, was sign
35 ibited enhanced inotropic sensitivity to the beta-adrenergic receptor agonist isoproterenol, with imp
36 l-4-phosphonophenylglycine (CPPG) and by the beta-adrenergic receptor agonist isoproterenol.
37 -) cells treated with 8-CPT-cAMP or with the beta-adrenergic receptor agonist isoproterenol.
38 tion of the Ca(2+) current stimulated by the beta-adrenergic receptor agonist isoproterenol.
39                    Chronic injections of the beta-adrenergic receptor agonist, isoproterenol, result
40 es were incubated with forskolin or with the beta-adrenergic receptor agonist, isoproterenol, to stim
41 lular signal-regulated kinases (ERKs) by the beta-adrenergic receptor agonist, isoproterenol.
42 following administration of isoproterenol, a beta-adrenergic receptor agonist known to induce cardiac
43 a condition associated with increases in the beta-adrenergic receptor agonist norepinephrine.
44  activity by forskolin, cAMP analogs, or the beta-adrenergic receptor agonists norepinephrine and iso
45                                              beta-adrenergic receptor agonists prevent the effects of
46 ce remained responsive to stimulation by the beta-adrenergic receptor agonist, (S)-isoproterenol.
47                           Interestingly, the beta-adrenergic receptor agonists, salbutamol, arterenol
48                                              Beta-adrenergic receptor agonists such as isoproterenol
49 change after treatment with isoproterenol, a beta-adrenergic receptor agonist that causes turnover of
50 ulation can be triggered by isoproterenol (a beta-adrenergic receptor agonist) treatment.
51 ary epithelial bilayer, when stimulated with beta adrenergic receptor agonists, vasointestinal peptid
52 reated some cells with Compound 49b, a novel beta-adrenergic receptor agonist we have reported previo
53 ions of isoproterenol (a peripherally-acting beta-adrenergic receptor agonist) were administered in a
54 rly phase of LTP by pairing isoproterenol, a beta-adrenergic receptor agonist, with a weak train, sub